Relay Therapeutics (RLAY) shares jumped 15% on Tuesday.
The company reported positive initial data from its Phase 2 ReInspire trial for zovegalisib in PIK3CA-driven vascular anomalies.
A 60% volumetric response rate was achieved at 12 weeks. At the lowest dose of 100mg twice daily, 29% of patients responded.
No patients discontinued treatment due to adverse events. Dose reductions occurred in 23% of patients.
Clinical improvement was reported in 89% of patients by investigators, and 79% by patients themselves.
Relay is also running a Phase 3 trial in HR+/HER2- advanced breast cancer.
Data were presented at the ISSVA World Congress in Philadelphia.
